Captopril in the Treatment of Hypertension
Authors: HARALAMBOS GAVRAS
Journal: Annals of Internal Medicine (1981)

Editorials1 October 1981Captopril in the Treatment of HypertensionHARALAMBOS GAVRAS, M.D., HANS R. BRUNNER, M.D., IRENE GAVRAS, M.D.HARALAMBOS GAVRAS, M.D.Search for more papers by this author, HANS R. BRUNNER, M.D.Search for more papers by this author, IRENE GAVRAS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-95-4-505 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIntensive research on the components of the reninangiotensin system over the past 2 decades has finally culminated in the introduction of a new mode of therapy for hypertension, inhibition of the angiotensin-converting enzyme. This enzyme catalyzes the last step in the formation of angiotensin II, a potent vasoconstrictor and steroidogenic hormone whose participation in the development and maintenance of hypertension is now well established.This novel approach to antihypertensive treatment is now being added to the existing three broad categories of antihypertensive drugs: diuretics, sympatholytic agents, and vasodilators. Angiotensin-Converting enzyme inhibitors have effects most comparable to those of vasodilators except...References1. ONDETTIRUBINCUSHMAN MBD. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science. 1977;196:441-4. CrossrefMedlineGoogle Scholar2. FERGUSONBRUNNERTURINIGAVRASMCKINSTRY RHGHD. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977;1:775-8. CrossrefMedlineGoogle Scholar3. SPERTINIBRUNNERWAEBERGAVRAS FHBH. The opposing effects of chronic angiotensin-converting enzyme blockade by Captopril on the responses to exogenous angiotensin II and vasopressin versus norepinephrine in rats. Circ Res. 1981;48:612-8. CrossrefMedlineGoogle Scholar4. MURTHYWALDRONGOLDBERT VTM. The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ 14,225 in conscious rabbits. Circ Res. 1978;43 (suppl I):I-40-5. Google Scholar5. GAVRASBRUNNERTURINI HHG. Antihypertensive effect of the oral angiotensin converting enzyme-inhibitor SQ 14225 in man. N Engl J Med. 1978;298:991-5. CrossrefMedlineGoogle Scholar6. BRUNNERWAEBERWAUTERSTURINIMCKINSTRYGAVRAS HBJGDH. Inappropriate renin secretion unmasked by captopril (SQ 14225) in hypertension of chronic renal failure. Lancet. 1978;II:704-7. CrossrefGoogle Scholar7. WAEBERGAVRASBRUNNERGAVRAS BIHH. Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol. In press. Google Scholar8. PANAYIWOOLEYBATCHELOR GPJ. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J. 1978;2:1326-8. CrossrefMedlineGoogle Scholar9. PATCHETTHARRISTRISTRAM AEE. A new class of angiotensin-converting enzyme inhibitors. Nature. 1980;288:280-3. CrossrefMedlineGoogle Scholar10. HOORNTJEKALLENBERGWEENINGDONKERTJWANHOEDEMAEKER SCJAHP. Immune-complex glomerulopathy in patients treated with Captopril. Lancet. 1980;1:1212-4. CrossrefMedlineGoogle Scholar11. GAVRASGRAFFROSEMCKENNABRUNNERGAVRAS ILBJHH. Fatal pancytopenia associated with the use of captopril. Ann Intern Med. 1981;94:58-9. LinkGoogle Scholar12. PIPKINTURNERSYMONDS FSE. Possible risk with captopril in pregnancy: some animal data. Lancet. 1980;1:1256. Letter. CrossrefGoogle Scholar13. TURINIBRUNNERGRIBICWAEBERGAVRAS GHMBH. Improvement of chronic congestive heart-failure by oral captopril. Lancet. 1979;1:1213-5. CrossrefMedlineGoogle Scholar14. MIMRANBRUNNERTURINIWAEBERBRUNNER AHGBD. Effect of captopril on renal vascular tone in patients with essential hypertension. Clin Sci. 1979;57:421-3. CrossrefMedlineGoogle Scholar15. LARAGHCASEATLASSEALEY JDSJ. Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension. 1980;2:586-93. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HARALAMBOS GAVRAS, M.D.; HANS R. BRUNNER, M.D.; IRENE GAVRAS, M.D.Affiliations: Department of Medicine Thorndike Memorial Laboratories Boston City Hospital Boston Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRole of renal and extrarenal reninangiotensin system in the mechanism of arterial hypertension and its sequelaeLichenoid eruption and alopecia associated with captopril treatmentAcute Effects of the New Angiotensin-Converting Enzyme Inhibitor Cilazapril: A Pilot StudyHypertension in the elderly: pathophysiology and its implications for treatmentCaptopril and EnalaprilIRENE GAVRAS, M.D., HARALAMBOS GAVRAS, M.D.Effect of captopril on normal and injured hemopoietic stem cellsCaptopril-Induced Granulocyte Aggregation. A Possible Complement Mediated Mechanism of Peripheral Leukopenia 1 October 1981Volume 95, Issue 4Page: 505-506KeywordsAngiotensin converting enzymeAngiotensin converting enzyme inhibitorDiureticsDrugsEnzymesHypertensionSteroid hormonesVasodilators ePublished: 1 December 2008 Issue Published: 1 October 1981 PDF downloadLoading ...